Advancement of the Third Generation of Antihistamines
- 1 January 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Pediatric Asthma, Allergy & Immunology
- Vol. 13 (4) , 163-168
- https://doi.org/10.1089/pai.1999.13.163
Abstract
Antihistamines are among the most commonly administered drugs in the world. They provide relief from the symptoms of allergies. The widespread need and use of antihistamines has fueled intense research and development for new and improved drugs. Antihistamines have evolved considerably since the first drugs with clinically useful antiallergic properties were introduced more than half a century ago. The elucidation of histamine receptor subtypes and of the molecular mechanisms that dictate drug potency, tissue distribution, and metabolism, as well as other advances in basic research, have driven the evolution of this class of therapeutics. Consequentially, the antihistamine drugs available to modern consumers, as well as many in development, are more efficacious, have reduced side effects, and are available in once-daily oral dosage form. This review will focus on the major developments in antihistamine therapy that have occurred in the latter half of this decade. The advancement of active isomers or metabolites of the nonsedating, second-generation of drugs to produce a third generation of superior agents will be discussed.Keywords
This publication has 13 references indexed in Scilit:
- Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscleEuropean Journal of Pharmacology, 1999
- QT lengthening and arrhythmias associated with fexofenadineThe Lancet, 1999
- QT lengthening and life-threatening arrhythmias associated with fexofenadineThe Lancet, 1999
- NorastemizoleDrugs of the Future, 1998
- Sedation and performance issues in the treatment of allergic conditionsArchives of internal medicine (1960), 1997
- Comparison of the central nervous system effects produce by six H1‐receptor antagonistsClinical and Experimental Allergy, 1996
- Cardiac Actions of AntihistaminesAnnual Review of Pharmacology and Toxicology, 1996
- The Pharmacology and Use of H1-Receptor-Antagonist DrugsNew England Journal of Medicine, 1994
- Definition and Antagonism of Histamine H2-receptorsNature, 1972
- The physiological action of β‐iminazolylethylamineThe Journal of Physiology, 1910